A new depression treatment arrives
Ketamine — or a chemical related to it — is officially set to become a part of the pharmaceutical repertoire to treat depression.
The FDA late yesterday approved Janssen's esketamine, the first major depression treatment to reach U.S. market in decades. Delivered as a nasal spray, the treatment will include a warning that patients who take it will be at risk for sedation and issues with attention, judgement, and thinking.
Janssen, a subsidiary of Johnson & Johnson, said the cost of the treatment will depend on the dose used per session and how many sessions a person will need, both of which can vary. The wholesale acquisition cost: between $590 and $885 per treatment session.
Read more.
The FDA late yesterday approved Janssen's esketamine, the first major depression treatment to reach U.S. market in decades. Delivered as a nasal spray, the treatment will include a warning that patients who take it will be at risk for sedation and issues with attention, judgement, and thinking.
Janssen, a subsidiary of Johnson & Johnson, said the cost of the treatment will depend on the dose used per session and how many sessions a person will need, both of which can vary. The wholesale acquisition cost: between $590 and $885 per treatment session.
Read more.
.png)
No hay comentarios:
Publicar un comentario